Regulatory Decisions: FDA decisions regarding Alkermes' drug approvals or rejections significantly impact investor confidence and stock price.

Clinical Trial Results: Positive clinical trial data boosts investor optimism, driving the stock price up, while negative results can lead to a decline.

Market Competition: The presence of competing drugs or therapies can affect Alkermes' market share and revenue, thereby influencing its stock valuation.

Financial Performance: Alkermes' revenue, earnings, and profitability are key indicators of its financial health, directly impacting investor sentiment.

Patent Protection: The strength and duration of Alkermes' patent portfolio for its key drugs influence its long-term revenue potential.

General Market Conditions: Broader market trends, economic conditions, and investor sentiment can affect the overall stock market and ALKS stock.

Partnerships and Collaborations: Agreements with other pharmaceutical companies or research institutions can affect the perceived value of Alkermes.

Debt Levels: Alkermes' debt burden and ability to manage its financial obligations influence investor confidence and stock performance.

Management Changes: Significant changes in Alkermes' leadership team can impact investor perceptions of the company's future direction.

Analyst Ratings: Analyst upgrades or downgrades of ALKS stock can influence investor decisions and trading activity.